<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358979</url>
  </required_header>
  <id_info>
    <org_study_id>EGN_2017_15</org_study_id>
    <nct_id>NCT03358979</nct_id>
  </id_info>
  <brief_title>Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE)</brief_title>
  <acronym>ALTESSE</acronym>
  <official_title>Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modifications of cell surface markers (including EMMPRIN) were observed in conjunctival
      epithelial cells during dry eye syndrome ; this study aims to describe the modifications of
      the repartition of these cell surface markers before and after initiation of a treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of surface area of cell markers measured on conjunctival epithelial cells, in persons with and without severe eye dryness.</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison of the mean surface in patients before treatment for eye dryness versus in persons with no eye dryness. Immunofluorescence analysed in confocal microscopy on conjunctival impression cytology.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Conjunctival Diseases</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Severe eye dryness</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>absence of eye dryness</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe eye dryness will be compared with persons without eye dryness.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients:

        Inclusion criteria

          -  18 years and over

          -  Severe eye dryness (grade 3 or 4) as defined by the International Dry Eye Work Shop
             (2007): Frequent symptoms, Impregnation of fluorescein at the conjunctival level,
             marked fluorescein staining at the corneal level, Tear Break Up Time ≤ 5 seconds
             (fluorescein test) Schirmer's test score without anesthesia ≤ 5mm at 5 minutes

        Exclusion criteria

          -  Treatment with topical ciclosporin

          -  Autologous serum treatment

          -  Wearer of scleral lenses

          -  Known pregnancy or breastfeeding

        Control subjects:

        Inclusion criteria

          -  18 years and over

          -  Tear Break Up Time &gt; 5 seconds (fluorescein test)

        Exclusion criteria

          -  Wearer of contact lenses

          -  Functional ocular signs

          -  Anomalies of the ocular surface observed during examination with the slit lamp

          -  Fluorescein staining of the ocular surface (cornea, conjunctiva)

          -  Topical ocular treatment

          -  Known pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric GABISON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence SALOMON</last_name>
    <phone>01.48.03.64.31</phone>
    <phone_ext>+33</phone_ext>
    <email>lsalomon@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric GABISON</last_name>
      <email>egabison@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conjunctival Diseases</keyword>
  <keyword>Dry Eye Syndromes</keyword>
  <keyword>Antigens</keyword>
  <keyword>CD147</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Conjunctival Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

